TLDR Legal & General (LGEN) fell ~6% on Wednesday after missing key analyst forecasts Core operating profit rose 6% to £1.62 billion, but came in slightly belowTLDR Legal & General (LGEN) fell ~6% on Wednesday after missing key analyst forecasts Core operating profit rose 6% to £1.62 billion, but came in slightly below

Legal & General (LGEN) Stock Falls 6% After Earnings Miss and Solvency Ratio Drop

2026/03/11 18:44
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Legal & General (LGEN) fell ~6% on Wednesday after missing key analyst forecasts
  • Core operating profit rose 6% to £1.62 billion, but came in slightly below estimates
  • Solvency II ratio dropped to 210% from 232%, missing forecasts
  • L&G launched its largest-ever share buyback of £1.2 billion
  • Total planned shareholder returns of £2.4 billion over the next year

Legal & General posted a 6% rise in annual core profit for 2025, but the market wasn’t impressed. The stock dropped sharply as analysts pointed to missed forecasts and a weaker solvency position.


LGEN.L Stock Card
Legal & General Group Plc, LGEN.L

Core operating profit came in at £1.62 billion. That was slightly below what analysts had expected. Profit before tax jumped 143% to £807 million — but that was well short of the roughly £1.19 billion consensus estimate.

Core earnings per share rose 9% to 20.93p, hitting the top end of L&G’s own 6–9% guidance range. The company said that was a positive sign for the direction of the business.

Still, investors sold off the stock. By mid-morning in London, LGEN was down around 5.7% to 243.8p — on track for its worst single day in 11 months.

The Solvency II coverage ratio was the other sticking point. It came in at 210%, down from 232% the year before. That missed analyst expectations too, and it’s a number the market watches closely as a measure of financial strength.

Shareholder Returns and Business Performance

Total planned returns to investors stand at £2.4 billion over the next 12 months, with more than £5 billion targeted between 2025 and 2027. Dividend per share growth is guided at 2%.

The pension risk transfer division had a strong year. L&G wrote £11.8 billion of global bulk annuity business, with £10.4 billion of that in the UK. Workplace defined-contribution assets under administration grew 21% to £114 billion.

Asset management showed improvement too. Private markets assets rose 32% to £75 billion, and average fee margins expanded to 9.1 basis points.

Monitoring the Iran War

L&G, which manages £1.1 trillion in assets, is keeping a close eye on market conditions. Simões said the company is monitoring the potential market impact of the expanding U.S.-Israeli war on Iran, which has pushed oil prices higher and raised concerns about the global economic outlook.

The company also flagged stresses in the U.S. private credit market as something on its radar. L&G struck a partnership with Blackstone in U.S. private credit last year, and Simões said its approach to high-quality credit has not changed.

Guidance for 2026 is for core operating EPS growth to remain at the top end of the 6–9% range, with healthy bulk annuity volumes expected to continue.

The post Legal & General (LGEN) Stock Falls 6% After Earnings Miss and Solvency Ratio Drop appeared first on CoinCentral.

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004282
$0.0004282$0.0004282
-3.53%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.